

AUGUST 2025 - PORTFOLIO UPDATE

The Australian market (XKOAI) rose again in August, up +3.2%. This is the fifth consecutive positive month. The market is now up +16% since the last negative month in March. The US was similar with S&P500 index rising +3.2%, however the tech-biased NASDAQ index managed only +1.6%. China (MSCI) +4.2% again outperformed as did Japan +4.0%. The UK (FTSE) +0.6% was more muted and Germany (DAX) fell -0.7%. Government 10-yr bond yields in both in the US and Australia barely moved. The Australian dollar rose +1.7%.

Australian reporting season saw extraordinary share price swings, with markedly different outcomes across the market. Small-caps surged +8.4% and mid-caps +5.5%, far exceeding the top 50 stocks at +2.1%. Much smaller Emerging Companies did the best of all delivering +9.9%. Value as a factor returned +7%, well ahead of Growth, which fell -3%.

The Ex-20 benchmark rose +4.1%, exceeding the overall market. The Quest portfolio returned +2.8%.

Gold stocks jumped +10% and was the best sector. Expectations of lower interest rates and a weaker US dollar lent support. Further earnings upgrades are likely for miners.

Discretionary retail +7.5% was also buoyant, with small retail doing especially well. The gain in the Autos +15% also stood out. Health -13% was clearly the worst sector reflecting hefty falls in large health stocks. Notably, the Tech sector fell -1.4%, explaining the poor showing by growth stocks. Commodities saw oil down -8% (WTIS) along with JKM LNG -7%, natural gas -4% and thermal coal. Iron ore +4% was well supported together with coking coal +6%, copper +2% and nickel +2%.

Reporting season once again delivered extreme stock movements, up and down. Small Industrials excelled with net earnings beat of over +20%, whilst the larger ASX100 stocks saw a net miss of -3%. Over 65% (by weight) of the Quest portfolio reported earnings that met or exceeded our expectations, whilst 24% did not report. That leaves 12% that disappointed, prominently Wistech -15%, Ramsay Healthcare -13% and Amcor -11%. These falls and lacklustre trading in Clarity Pharma -32% Superloop -14%, Immutep -13% and Catapult -6% weighed on portfolio returns.

Best performers were gold miners Vault Minerals +47% and Northern Star 21%, along with small caps EROAD +31%, and Qoria +12%. Seek +15%, Life360 +16% and NextDC +14% continued to deliver despite the general fall in the Tech sector.

Whilst lower interest rates should provide support, markets have now marched to record highs in a sustained, five-month rally. We are being careful to contain portfolio risk, taking profits in growth-oriented names and tilting towards defensive stocks. We are well placed to capitalise should there be any market weakness, with room made available in the portfolio.

PORTFOLIO FEATURES

Fund Name	Quest X20 Australian Equities Fund
Inception	19 October 2021
Benchmark	S&P/ASX300 ex 20 Index
No. of holdings	20 - 40
Typical cash weight	3 - 10%
Investment horizon	3 - 5 years
Portfolio Manager	Troy Cairns/ Swapan Pandya
APIR	ETL7425AU

HOW TO INVEST

Invest directly - click [here](#) for the PDS.

Also available on HUB24 Platform, Netwealth (Private Menu), Xplore Wealth, PowerWrap, Mason Stevens

RESEARCH RATINGS

Lonsec	HIGHLY RECOMMENDED^
--------	---------------------

DRIVERS OF PERFORMANCE

POSITIVE

Vault Minerals, EROAD, Northern Star, Seek, Life360, Qoria, Integral Diagnostics, Propel Funerals, Judo Capital

NEGATIVE

Clarity Pharmaceuticals, Wisetech, Ramsay Healthcare, GQG Partners, Amcor, Superloop, Immutep, Catapult

CURRENT PORTFOLIO

Total holdings	38
Non-benchmark holdings	5
Tracking error	5.41%
Active share	77.2%
Earnings growth (1yr fwd)*	26.5% pa
ROE	14%
Beta	1.00
P/E (1yr fwd)*	32.4x
Dividend yield (1yr fwd)	2.3%

Source: Bloomberg (*outliers excluded)

PERFORMANCE*

To 30 August 2025	1month	3months	6months	1yr	3yrs (p.a)	Inception* (pa)
Quest X20 Aust Equities Fund	+2.8%	+7.9%	+9.2%	+8.1%	+8.4%	+3.4%
ASX300 Acc. ex ASX20 index	+4.1%	+8.0%	+13.6%	+18.7%	+11.8%	+7.5%
Value added	-1.3%	-0.1%	-4.4%	-10.6%	-3.5%	-4.1%

* Inception 19 October 2021. Fund performance and value added is net of all fees. **Past performance is no guarantee of future performance.** Returns for periods 1year or greater are calculated on an annualised basis.



INVESTMENT PROFILE

The Quest X20 Portfolio is a Unit Trust, actively managed by Quest Asset Partners. The Portfolio comprises between 20 and 40 securities and aims to outperform the S&P/ASX 300 index excluding the 20 largest companies. This Unit Trust is managed in the same way as the Quest Ex-20 SMA (Separately Managed Account) which was established in January 2017. Performance for the Quest Ex-20 SMA is available on request.

The Portfolio will have significant exposure to mid and small-capitalised stocks benefiting from our proven investment process and experience with smaller companies.

The assessment of business quality is fundamental to the Quest investment process. We aim to identify companies that can deliver good returns on invested capital and sustain those returns through time. Quest has a long track record of investment performance leveraging this process.

The portfolio will typically have a bias to companies with growth characteristics (revenue, earnings and return on equity) and can be expected to have significant exposure to companies not in the benchmark. Both these exposures will vary through time as opportunities arise.

Portfolio risk is actively managed with a focus on capital preservation.

PORTFOLIO HOLDINGS*

LARGE CAP

Car Group	Resmed
Wisetech	Xero

MID CAP

AUB Group	ALS
SEEK	Ventia

SMALL CAP

Catapult	Dicker Data
Propel Funerals	Qoria

* Not complete list

CONTACT QUEST

Head of Distribution


Simon Wu
Email: [ph.0432 331 324
swu@questap.com.au](mailto:swu@questap.com.au)

Portfolio Manager

Troy Cairns
Email: [ph.02 9409 2303
tcairns@questap.com.au](mailto:tcairns@questap.com.au)

Swapan Pandya
Email: [ph.02 9409 2302
spandya@questap.com.au](mailto:spandya@questap.com.au)

PORTFOLIO 4 SEPT 2025



DISCLAIMER

Equity Trustees Limited ("Equity Trustees") ABN 46 004 031 298 | AFSL 240975, is the Responsible Entity for the Quest X20 Australian Equities Fund ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). The Investment Manager for the Fund is Quest Asset Partners Pty Ltd ("Quest") (ABN 47 109 448 802), AFSL 279 207. This publication has been prepared by Quest to provide you with general information only. In preparing this document, Quest did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Quest, Equity Trustees nor any of their related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should consider the Product Disclosure Statement ("PDS") before making a decision about whether to invest in this product.

Quest X20 Australian Equities Fund's Target Market Determination is available here www.eqt.com.au/insto. A Target Market Determination describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.

* The rating issued 10/2024 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2024 Lonsec. All rights reserved.

^ Ratings are only one factor to be taken into account when deciding whether to invest in a financial product. Ratings are subject to change.